This study discusses the technology assessment, and the cost-effectiveness, analysis in the incorporation of available technologies in the local market for the diagnosis of acute respiratory infection (ARI) in cancer patients treated at ICESP

• Grant number: 11/11999-3
• Support Opportunities: Regular Research Grants
• Start date: October 01, 2011
• End date: September 30, 2014
• Field of knowledge: Health Sciences - Collective Health - Epidemiology
• Principal Investigator: Eduardo Massad
• Grantee: Eduardo Massad
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Saulo Duarte Passos

Abstract

This study discusses the technology assessment, and the cost-effectiveness, analysis in the incorporation of available technologies in the local market for the diagnosis of acute respiratory infection (ARI) in cancer patients treated at ICESP. Despite the severity and frequency of respiratory infections in patients undergoing cancer treatment there is not available rapid diagnosis tests of major causative agents in the public health service. Furthermore, information about the cost of treating deadly infections is limited. With the increasing access to technology, increased the ease of identification of numerous pathogens by RT-PCR. In this study we propose the analysis of 25 agents between viruses and bacteria that can cause these infections as well as the analysis in the 12 months to the study of seasonality. The study aims to understand the frequency of severe cases by subtypes and the association of infections with more than one agent to evaluate if this might be an aggravating factor.The implementation of rapid tests to identify ARI patients at risk for complications can reduce the number of deaths and enable also the identification of potential patients for a safer outpatient treatment by reducing the number of hospitalizations, invasive procedures, directly impacting the quality of life patient. (AU)